Buntanetap

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBuntanetap
Drug Alias NamePosiphen(+)-PhenserineR-phenserineANVS-401ANVS-405
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMicrotubule-associated protein tau inhibitorsBeta amyloid A4 protein inhibitorsSynuclein alpha inhibitors
TargetsMicrotubule-associated protein tauBeta amyloid A4 proteinSynuclein alpha
Therapy Area/IndicationsCognitive DysfunctionDown SyndromeFrontotemporal Dementia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRaptor Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesAnnovis Bio Inc
Inactive CompaniesN/A
Active IndicationsDown SyndromeFrontotemporal DementiaAlzheimer Disease +[5] 
Inactive IndicationsCognitive Dysfunction

Other Information

ATC CodeN/A
Related LinksN/A